Cargando…
Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction
Voiding dysfunction due to detrusor underactivity or urethral sphincter dysfunction is a treatment challenge for urologists. Recently, urologists have used botulinum toxin A (BoNT-A) injection into the urethral sphincter to treat voiding dysfunction. This treatment has been found to decrease urethra...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442911/ https://www.ncbi.nlm.nih.gov/pubmed/28757732 http://dx.doi.org/10.1016/j.tcmj.2016.07.001 |
_version_ | 1783238495611912192 |
---|---|
author | Kuo, Hann-Chorng |
author_facet | Kuo, Hann-Chorng |
author_sort | Kuo, Hann-Chorng |
collection | PubMed |
description | Voiding dysfunction due to detrusor underactivity or urethral sphincter dysfunction is a treatment challenge for urologists. Recently, urologists have used botulinum toxin A (BoNT-A) injection into the urethral sphincter to treat voiding dysfunction. This treatment has been found to decrease urethral pressure and postvoid residual volume, and increase voiding efficiency in patients with neurogenic detrusor sphincter dyssynergia, nonneurogenic dysfunctional voiding, and detrusor underactivity. Although not all patients can achieve excellent therapeutic outcomes, patients with idiopathic detrusor underactivity might have recovery of detrusor contractility after urethral sphincter BoNT-A injection. However, urinary incontinence might be a de novo adverse event after treatment. Repeat urethral injection is necessary to maintain therapeutic efficacy. Patients should be fully informed of the limited therapeutic efficacy and possible adverse events prior to treatment. This article reviews recent studies of urethral sphincter BoNT-A treatment for voiding dysfunction. |
format | Online Article Text |
id | pubmed-5442911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-54429112017-07-26 Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction Kuo, Hann-Chorng Tzu Chi Med J Review Article Voiding dysfunction due to detrusor underactivity or urethral sphincter dysfunction is a treatment challenge for urologists. Recently, urologists have used botulinum toxin A (BoNT-A) injection into the urethral sphincter to treat voiding dysfunction. This treatment has been found to decrease urethral pressure and postvoid residual volume, and increase voiding efficiency in patients with neurogenic detrusor sphincter dyssynergia, nonneurogenic dysfunctional voiding, and detrusor underactivity. Although not all patients can achieve excellent therapeutic outcomes, patients with idiopathic detrusor underactivity might have recovery of detrusor contractility after urethral sphincter BoNT-A injection. However, urinary incontinence might be a de novo adverse event after treatment. Repeat urethral injection is necessary to maintain therapeutic efficacy. Patients should be fully informed of the limited therapeutic efficacy and possible adverse events prior to treatment. This article reviews recent studies of urethral sphincter BoNT-A treatment for voiding dysfunction. Medknow Publications & Media Pvt Ltd 2016 2016-08-28 /pmc/articles/PMC5442911/ /pubmed/28757732 http://dx.doi.org/10.1016/j.tcmj.2016.07.001 Text en Copyright: © 2016, Buddhist Compassion Relief Tzu Chi Foundation http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Kuo, Hann-Chorng Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction |
title | Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction |
title_full | Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction |
title_fullStr | Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction |
title_full_unstemmed | Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction |
title_short | Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction |
title_sort | botulinun a toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442911/ https://www.ncbi.nlm.nih.gov/pubmed/28757732 http://dx.doi.org/10.1016/j.tcmj.2016.07.001 |
work_keys_str_mv | AT kuohannchorng botulinunatoxinurethralsphincterinjectionforneurogenicornonneurogenicvoidingdysfunction |